Exabis Library
Welcome to the e-CCO Library!
P596 Risk of colorectal cancer and other malignancies in association with the use of thiopurines, tumour necrosis factor antagonists or mesalazine
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P596: Adalimumab use in Paediatric Inflammatory Bowel Disease: A single centre real-life experience
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P596: An ongoing safety registry to identify rare and severe complications in children with paediatric-onset IBD
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P596: Clinical utility of vedolizumab trough levels and anti-drug antibodies in the management of IBD
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P596: FMT in patients with steroid dependant ulcerative colitis a single centre observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P596: Trough concentration of ustekinumab was a useful biomarker for the prediction of treatment-effects in patients with Crohn’s Diseases.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P596: Ustekinumab and anti-TNF agents are equally safe and effective in elderly Crohn's disease patients: A propensity adjusted multi-centre cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P597 Pooled safety analyses from Phase 3 studies of filgotinib in patients with rheumatoid arthritis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P597: Bone mineral density in patients after total proctocolectomy and pouch surgery due to Ulcerative Colitis have low bone mineral density, and low performance of DXA scans- a cross sectional study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P597: Cycling Anti-TNF Therapy in Inflammatory Bowel Disease: Effectiveness and Durability of Switching from adalimumab to infliximab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P597: Effectiveness and safety of vedolizumab therapy in an ulcerative colitis cohort with significant prior anti-TNF exposure
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P597: Optimising therapeutic drug monitoring of adalimumab with dried blood samples in IBD patients: an interim analysis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P597: Usefulness of histological monitoring in predicting relapse after de-escalation of thiopurines in Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P597: Ustekinumab use in Crohn's disease: a tertiary centre experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P598 Incidence of venous thromboembolic events in patients with ulcerative colitis treated with tofacitinib in the ulcerative colitis clinical development programme: An update as of May 2019
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P598: Adherence to treatment in IBD: to see beyond motivation
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P598: Indicators for inadequate response among patients with Ulcerative Colitis treated with advanced therapies in German clinical practice
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P598: Mucosal and transmural healing during anti-TNF therapy. Is fecal calprotectin a marker of therapeutic response?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P598: Previous Intestinal Resection Is Associated with Postoperative Complications in Crohn’s Disease: A Cohort Study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P598: Safety and effectiveness of adalimumab treatment in 1523 patients with ulcerative colitis: Results from a prospective, multi-centre, observational study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM